SCHEMBL16636607

SCHEMBL16636607

N#C/C(=C\c1csc2nc(CCl)cc(=O)n12)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.50
ALDH1A1 P00352 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
POLB P06746 6/20 0.41
APEX1 P27695 1/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TP53 P04637 3/20 0.35
MAPT P10636 1/20 0.35
RXFP1 Q9HBX9 4/20 0.33
EGFR P00533 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
GAA P10253 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636608 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1NPSR1POLBAPEX1
SCHEMBL17975713 0.85 ATM (0.45) L3MBTL1ALDH1A1NPSR1POLBHTT
SCHEMBL16636487 0.78 L3MBTL1 (0.58) L3MBTL1ALDH1A1NPSR1POLBAPEX1
SCHEMBL16636596 0.70 L3MBTL1 (0.58) L3MBTL1ALDH1A1NPSR1POLBAPEX1
SCHEMBL636234 0.69 L3MBTL1 (0.60) L3MBTL1ALDH1A1NPSR1POLBAPEX1
SCHEMBL16636644 0.68 L3MBTL1 (0.47) L3MBTL1ALDH1A1NPSR1POLBAPEX1
SCHEMBL10996879 0.67 ALDH1A1 (1.00) L3MBTL1ALDH1A1NPSR1POLBMEN1
SCHEMBL16636490 0.66 ALDH1A1 (0.53) L3MBTL1ALDH1A1NPSR1POLBAPEX1
SCHEMBL16636745 0.64 L3MBTL1 (0.51) L3MBTL1ALDH1A1NPSR1POLBAPEX1
SCHEMBL10998811 0.63 ALDH1A1 (0.54) L3MBTL1ALDH1A1NPSR1POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647731-B2 Thiazolopyrimidinones and methods of use thereof GENENTECH, INC. (US) 2020-05-12 US disclosed
EP-3415519-A1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY F. Hoffmann-La Roche AG (CH) 2018-12-19 EP disclosed
US-20180244694-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-08-30 US disclosed
EP-3055315-B1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2018-07-25 EP disclosed
US-9988400-B2 Thiazolopyrimidinones and methods of use thereof GENENTECH, INC. (US) 2018-06-05 US disclosed
EP-3055315-A1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY F. Hoffmann-La Roche AG (CH) 2016-08-17 EP disclosed
US-20160222033-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-08-04 US disclosed
WO-2015052226-A1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647731-B2 Thiazolopyrimidinones and methods of use thereof TPMT, THPO, CYP11B2 L3MBTL1 4804/4885ALDH1A1 159/4885NPSR1 1484/4885
US-20180244694-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF TPMT, THPO, CYP11B2 L3MBTL1 4804/4885ALDH1A1 159/4885NPSR1 1484/4885
US-20160222033-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF TPMT, THPO, CYP11B2 L3MBTL1 4804/4885ALDH1A1 159/4885NPSR1 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.